Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIO752 in Alzheimer's Disease
NCT06372821Phase 1Recruiting
- Sponsor
- University College London
- Start
- Nov 2024
- Primary completion
- Jul 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of NIO752 in Alzheimer's disease (AD) (2 arms), sponsored by University College London. Primary endpoint: Tau synthesis rate inhibition at Day 23. Started Nov 2024; status: recruiting.
02
Drugs
NIO752
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06372821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372821.